Enhertu secures positive EU panel backing for first pan-tumor HER2 therapy
Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.



_1405545_640x360_2501025859508-640x360.webp&w=3840&q=75)


_1405519_640x360_2501023299537-640x360.webp&w=3840&q=75)

_1405473_640x360_2501024323554-640x360.webp&w=3840&q=75)
_1405449_640x360_2501017155965-640x360.webp&w=3840&q=75)

